Topic: bone marrow transplant
A drug could boost stem cell counts in cord blood, and new data show it could hold promise for treating blood cancer patients.
Pfizer’s ED drug Viagra facilitates the release of stem cells from the bone marrow into the bloodstream, which could ease collection.
Transplanting T-cells to immunotherapies could lead to better results in non-Hodgkin lymphoma, Mount Sinai scientists have found.
The blood cancer-focused immunotherapy company Kiadis Pharma is bringing on Robert Friesen, Ph.D., to serve as its chief scientific officer.
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Magenta’s MGTA-456 hit efficacy targets in the first patients from a phase 2 trial that will drop at ASH next month, but with a question about safety.
The week’s biotech news included a potential boost to cancer immunotherapy and new insight into a dementia-causing protein.
Kalytera is developing cannabidiol for the prevention and treatment of graft-versus-host disease, a serious complication of bone marrow transplant.
Coming off the back of a healthy financing round just six weeks ago, stem cell biotech Magenta Therapeutics now wants more, and it wants to go public.
Semma Therapeutics named Bastiano Sanna, formerly of Novartis’ cell and gene therapy unit and Magenta Therapeutics, as its president and CEO.